Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 8/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 7/20 | 0.50 |
| ▸ | PLK4 | O00444 | 3/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | MARK3 | P27448 | 3/20 | 0.50 |
| ▸ | TYK2 | P29597 | 3/20 | 0.50 |
| ▸ | CLK2 | P49760 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460577 | 0.85 | JAK2 (0.56) | SGK1ROCK1CLK4PRKD3LIMK1 | |
| SCHEMBL1461070 | 0.82 | ITK (0.60) | SGK1ROCK1CLK4PRKD3LIMK1 | |
| SCHEMBL4003124 | 0.81 | ROCK1 (0.54) | SGK1ROCK1CLK4PRKD3LIMK1 | |
| SCHEMBL1460752 | 0.76 | ROCK1 (0.58) | SGK1ROCK1CLK4PRKD3LIMK1 | |
| SCHEMBL27676127 | 0.73 | JAK2 (0.54) | SGK1ROCK1CLK4PRKD3LIMK1 | |
| SCHEMBL28270280 | 0.73 | HTR6 (0.61) | PKM | |
| SCHEMBL29530798 | 0.73 | HTR6 (0.61) | PKM | |
| SCHEMBL1460534 | 0.72 | ITK (0.66) | SGK1AURKBITK | |
| SCHEMBL1461696 | 0.71 | MAP2K4 (0.56) | AURKBITK | |
| SCHEMBL1460521 | 0.70 | ITK (0.60) | AURKBKDRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4643910-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| JP-2005533004-A | — | — | 2005-11-04 | — | — | JP | claimed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | claimed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | SGK1 192/4885ROCK1 451/4885CLK4 608/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | SGK1 241/4885ROCK1 437/4885CLK4 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.